DRUG CARDS DAILY

Name(s)

Generic: warfarin (WAR far in) | Brand: Coumadin, Jantoven

Therapeutic Category

Anticoagulant | Vitamin K Antagonist

Indication(s)

- 1. Myocardial infarction (MI): Warfarin is used to reduce systemic embolism risk after MI.
- 2. Thromboembolic complications: Warfarin is used as a preventative measure as well as in the treatment of various thromboembolic disorders such as venous and pulmonary thrombosis. It is also beneficial in treating and preventing complications due to cardiac valve replacements and embolic complications secondary to atrial fibrillation. It is important to note that warfarin does not reverse damage but rather to prevent additional damage.

Dosage Form & Strength

Tablet: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 7.5 mg, 10 mg

Dosing by Indication

• Dosing Adults on Anticoagulation Therapy:

.

- There is high variability due to genetic variations between patients as well as other factors such as diet, age, and race.
- INR stands for International Normalized Ratio and is a measurement used for measuring the level of therapeutic effect of the anticoagulation. A high value corresponds with a high level of anticoagulation.
- It is also important to note that INR elevation is often seen between 24-48 hours but that INR may not represent therapeutic anticoagulation.
- Unless guided by a patient-specific factor (VKORC1, CYP2C9, race, age, etc.) initiate dosing at <u>5 mg po qd for 3 days</u>. Check INR the morning of day 4. If...
 - INR <1.5 Give pt 7.5-10 mg po qd for 2-3 days
 - INR 1.5-1.9 Give pt 5 mg po qd for 2-3 days
 - INR 2-3 Give pt 2.5 mg po qd for 2-3 days
 - INR 3.1-4 Give pt 1.25 mg po qd for 2-3 days
 - INR >4
 Hold doses until INR is <3
- As mentioned dosing is highly pt-specific and <u>dosing must change accordingly</u>. For example; if a pt-specific <u>sensitivity</u> exists initiate at a <u>lower dose</u>. Now for this patient, <u>initiate 2.5 mg po qd for 3 days</u>. Check INR the morning of day 4. If...
 - INR <1.5 Give pt 5-7.5 mg po qd for 2-3 days
 - INR 1.5-1.9 Give pt 2.5 mg po qd for 2-3 days
 - INR 2-3 Give pt 1.25 mg po qd for 2-3 days
 - INR 3.1-4 Give pt 0.5 mg po qd for 2-3 days
 - INR >4 Hold doses until INR is <3
- General maintenance dose is between 2-10 mg po qd. Maintenance dosing is based on a stable and therapeutic INR based on intensity. A regular intensity of anticoagulation has an INR goal between 2-3 while high-intensity is between 2.5-3.5.
 Maintenance dosing nomograms may vary from institution. An example for regular intensity anticoagulation dosing is as follows:
 - Patient is subtherapeutic (LOW):
 - INR < 1.5 | Increase weekly dose by 10-20% or one time dose between 1.5 to 2 times the daily maintenance dose.
 - INR 1.5-1.7 | Increase weekly dose by 5-15% or one time dose between 1.5 to 2 times the daily maintenance dose.
 - **INR 1.8-1.9** | If last two INRs were in range and no explanation for change do not adjust dose. If clinical judgment warrants dose change, increase weekly dose by 5-15% or one time dose between 1.5 to 2 times the daily maintenance dose.
 - INR in range:



DRUG CARDS DAILY

PODCAST: +)) anchor.fm/DrugCardsDaily

TWITTER: y twitter.com/DrugCardsDaily

- INR 2-3 | No dose adjustments made
- INR in supratherapeutic (HIGH):
 - INR 3.1-3.2 | No dose adjustment is made if there is no clear reason why INR changed. Otherwise decrease weekly dose by 5-10%
 - INR 3.3-3.4 | Decrease weekly dose by 5-10%
 - INR 3.5-3.9 | Consider holding one dose. Decrease weekly dose by 5-10%
 - INR >4 but ≤10 | Hold dose until INR below upper limit of therapeutic range. Decrease weekly dose by 5-20%. If pt at severe risk for bleeding consider low-dose oral vitamin K
 - INR >10 w/o bleeding | Hold dose until INR below upper limit of therapeutic range. Decrease weekly dose by 5-20%. Administer oral vitamin K
- Target INR ranges are based on indication: Check with most current ACCP guidelines for appropriate INR ranges and duration of treatments. I will cover just a few so you know what to expect. For example...
 - Cardiac patients:
 - MI w/ left ventricular thrombus or if high risk for left ventricular thrombus the target INR is 2-3 with a treatment duration of 3 months after MI.
 - Afib or Aflutter the INR is 2-3 with an indefinite treatment duration
 - Stress cardiomyopathy w/ acute left ventricular thrombus INR is 2-3 w/ a treatment duration of 3 months.
 - **Valvular** patients (aspirin indefinitely in combination w/ warfarin):
 - On-X mechanic bileaflet aortic valve w/ no additional risk factors for thromboembolism the INR range is 2-3 (months 1-3) then 1.5-2 (month 4 and after) w/ an indefinite treatment duration.
 - Mechanical aortic value or older-gen value <u>WITH additional risk</u> factors for thromboembolism the INR range is 2.5-3.5 w/ an indefinite treatment duration.
 - Surgically placed bioprosthetic aortic or mitral valve at lower bleed risk the INR range is 2-3 w/ a treatment duration of 3-6 months.
- **Transitioning between anticoagulants:** Check with most current guidelines for accuracy. I will cover just a few as an example of what to expect. For example...
 - Apixaban → warfarin: Consider overlapping apixaban w/ warfarin for ≥2 days until INR is therapeutic. Alternative method is to stop apixaban and start warfarin the same day while bridging patient w/ a parenteral anticoagulant such a heparin
 - Parenteral anticoagulant → warfarin: Start warfarin while continuing parenteral anticoagulant until goal INR is achieved.
- Transitioning from warfarin to a different anticoagulant: Check with most current guidelines for accuracy. I will cover just a few as an example of what to expect. For example...
 - o It is reasonable to d/c warfarin and initiate the other anticoagulant once INR is ≤2 or pt-specific INR goal.
 - Warfarin \rightarrow apixaban: D/c warfarin. Initiate apixaban as soon an INR falls to <2
 - Warfarin → dabigatran: D/c warfarin. Initate dabigatran as soon as INR falls to <2
 - Warfarin \rightarrow edoxaban: D/c warfarin and initiate edoxaban as soon as INR falls to ≤ 2.5
 - Warfarin → parenteral anticoagulant: Stop warfarin and start parenteral anticoagulant when INR is as close as possible to the lower end of the INR range that is desired.

Mechanism of Action & Pharmacology

- MOA: In order to understand how warfarin competitively inhibits coagulation factors we must understand the synthesis of various clotting factors. Vitamin K is an essential part of the hepatic synthesis of coagulation factors II, VII, IX, and X; as well as proteins C and S. In order for the coagulation factors to be converted active vitamin K must give up a carboxyl group in order for the conversion to occur. Vitamin K is then reactivated by the vitamin K epoxide reductase complex 1 (VKORC1). Warfarin inhibits VKORC1 which inhibits coagulation factors 2, 7, 9, and 10.
- Absorption is rapid and complete | Metabolism is hepatic through the CYP2C9 pathway and to a lesser extent the CYP2C8, 2C18, 2C19, 1A2, and 3A4 pathways. It is important to remember to identify genomic variations of CYP2C9. The heterozygous *1/*2 or *1/*3 genomic variant has approximately a 37% reduction in clearance. Patients with the homozygous *2/*2, *2/*3, *3/*3 allele variants have approximately 70% reduced metabolism function. | Onset of Action: Initial effects on INR are as soon as 24-72 hours but the full therapeutic benefits are seen between 5-7 days being limited by factor II's (prothrombin's) long half-life of 60-72 hours | Time to Peak is



DRUG CARDS DAILY

FOLLOW ME!

around 4 hours | Duration of Action is between 2-5 days | Half-Life Elimination is between 20-60 hours with an average of 40 hours | Highly protein bound at 99%

Special Populations & Considerations

- Hepatically impaired patients experience a decreased metabolism of warfarin while renally impaired patients generally respond as expected.
- Elderly patients 60 years of age and older have a higher sensitivity regarding INR responses
- Race plays a role in the Asian population requiring lower initial doses and lower maintenance doses.
- Pharmacogenetics is an important factor to consider. VKORC1 and CYP2C8 genetic variations will aid in determining variability with patient dosing
- **Pregnancy:** If reproductive potential exists pt should use contraceptive during therapy and for 1 month after last dose of warfarin. Warfarin crosses placenta and teratogenic effects have been reported in first trimester. Pregnant women that require anticoagulant that are high-risk patients and must be on an anticoagulant data suggests the use of LMWH or an adjusted-dose heparin but always refer to most current data and consider patient-specific factors.

Side Effect

- Nausea, abdominal pain, loss of appetite, diarrhea, dizziness
- Serious side effects that require immediate attention: Bleeding gums, blood in urine/stool, blurred vision, chest pain, difficulty breathing/swallowing, confusion.

BLACK BOX WARNING: <u>Bleeding Risk</u> – May cause major and/or fatal bleeding. Monitor INR regularly for all patients. Monitor all drug and dietary changes on warfarin therapy. Teach patients on how to measure and minimize bleed risk.

Drug Interactions

- Acetaminophen may enhance anticoagulant effects in doses exceeding 1.3-2 grams per day for multiple days.
- Alcohol may decrease effects
- Barbituates may increase the metabolism of warfarin. Dose increases between 30-60% may be needed while on barbituates.
- Clopidogrel and NSAIDs may enhance anticoagulant effects of warfarin
- Dose adjustments should be made if patient is on any CYP2C9 inducers/inhibitors

Monitoring Parameters

- International Normalized Ratio (INR)
 - Initiation: Daily if inpatient; outpatient 3-5 days if stable and 1-3 days if unstable
 - Maintenance: If stable every 1-3 days, if unstable daily; If routine f/u every 4-12 weeks if stable and every 1-2 weeks if unstable. If dose was held recheck in 1-2 days. If dose adjusted (today) recheck w/in 1-2 weeks. If dose adjusted (≤2 weeks ago) recheck w/in 2-4 weeks.
- Genetic testing for CYP2C9 and VKORC1 genotype prior to initiation
- Irregular bleeding and bruising; Kidney function; Dietary changes

Patient Counseling Information

- Used to treat blood clots and thins blood to lower chance of heart attack, stroke, and death.
- Can be taken w/ or w/o food.
- Usually administered once daily at the same time each day
- High vitamin K foods such as leafy greens inhibit anticoagulation so patients should not make drastic changes diet.


Reference(s)

- https://www.drugs.com/ppa/warfarin.html
- <u>https://www.webmd.com/drugs/2/drug-3949/warfarin-oral/details</u>



PREPARE FOR SUCCESS!

Comprehensive (NAPLEX)



This page contains affiliate links. Buying something through a link will provide a small monetary commission to Drug Cards Daily at no cost to you! This is done to keep Drug Cards Daily going and to provide as much free content to people like you! Thank you so very much for your support! Also, images are property of their respective parties and can be removed by contacting Drug Cards Daily.

DISCLAIMERS

DRUG CARDS D A I L Y

Monday at 7 am EST (6 am CST, 4 am PST)

HEY NEW GRAD!

So you landed that perfect job offer or got the perfect match for your PGY1 and now the <u>ONLY</u> thing standing in your way is passing the NAPLEX and MPJE.

Here are some NAPLEX & MPJE prep recommendations to help you do everything you can to **pass the first time!**

HEY STUDENT!

When I was P1 one of the best pieces of advice I got from those before me was to use a NAPLEX Prep book while learning each topic.

This helps focus your learning and the repetition helps to retain info and indirectly prepare you for the NAPLEX

